Treatment for early-stage lung cancer: what next?

  title={Treatment for early-stage lung cancer: what next?},
  author={Luis Paz-Ares and Jes{\'u}s Corral},
  journal={The Lancet},
Lung cancer is the leading cause of cancer-related mortality worldwide, accounting for 19% of cancerrelated deaths. This devastating toll is the consequence of a high incidence (1·8 million new diagnoses in 2012) and a low rate of cure. Most patients continue to be diagnosed at advanced disease stages. Moreover, the outcome of patients who present with resectable and operable lung cancer (about 25% of cases) is substantially worse than that noted in many other earlystage solid tumours, with… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 12 times. VIEW TWEETS


Publications referenced by this paper.
Showing 1-10 of 14 references

A randomised trial comparing preoperative to perioperative chemotherapy in early - stage non - small - cell lung cancer ( IFCT 0002 trial )

P Rastogi, SJ Anderson, HD Bear
Eur J Cancer • 2013

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2013

Survival study of neoadjuvant versus adjuvant chemotherapy with docetaxel combined carboplatin in resectable stage IB to IIIA non - small cell lung cancer

V Westeel, E Quoix, M Puyraveau

Similar Papers

Loading similar papers…